CARDIOL THERAPEUTICS
Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol Therapeutics leverages their expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in two important medical markets: commercializing a line of pharmaceutical cannabidiol products in the growing market for medical cannabinoids and developing nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs to the heart for the treatment of inflammatory heart disease.
CARDIOL THERAPEUTICS
Industry:
Biotechnology Life Science Nanotechnology
Founded:
2017-01-01
Address:
Oakville, Ontario, Canada
Country:
Canada
Website Url:
http://www.cardiolrx.com
Total Employee:
11+
Status:
Active
Contact:
289.910.0850
Email Addresses:
[email protected]
Total Funding:
76.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Employees Featured
Founder
Stock Details
Investors List
Raymond James
Raymond James investment in Post-IPO Equity - Cardiol Therapeutics
Canaccord Genuity Group
Canaccord Genuity Group investment in Post-IPO Equity - Cardiol Therapeutics
AlbaCore Capital
AlbaCore Capital investment in Post-IPO Equity - Cardiol Therapeutics
Echelon Wealth Partners
Echelon Wealth Partners investment in Post-IPO Equity - Cardiol Therapeutics
Official Site Inspections
http://www.cardiolrx.com Semrush global rank: 7.26 M Semrush visits lastest month: 548
- Host name: 65.39.134.189
- IP address: 65.39.134.189
- Location: Toronto Canada
- Latitude: 43.6683
- Longitude: -79.4205
- Timezone: America/Toronto
- Postal: M6G
More informations about "Cardiol Therapeutics"
Company - Cardiol Therapeutics
The Company’s lead small molecule drug candidate, CardiolRxâ„¢ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart …See details»
Investor Relations - Cardiol Therapeutics
Our lead small molecule drug candidate, CardiolRxâ„¢ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart …See details»
Cardiol Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 289.910.0850 Cardiol Therapeutics focuses on producing pharmaceutical cannabidiol products and developing innovative therapies for heart …See details»
Cardiol Therapeutics Inc. (CRDL) Company Profile & Overview
6 days ago Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of …See details»
Cardiol Therapeutics Inc. - LinkedIn
Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti …See details»
Cardiol Therapeutics Receives Health Canada Approval for Phase II ...
Oct 25, 2021 Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis Newsfile Corp. Mon, Oct 25, 2021, 7:27 AM 5 min readSee details»
Cardiol Therapeutics Announces FDA Investigational New Drug …
May 17, 2022 Third IND authorization for CardiolRxâ„¢ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence …See details»
CardiolRx - Drug Targets, Indications, Patents - Synapse - Patsnap
Jun 13, 2023 Administration of CardiolRxâ„¢ led to a marked reduction in the primary efficacy endpoint of pericarditis pain CardiolRxâ„¢ also shown to reduce inflammation in patients with …See details»
Our Focus - Cardiol Therapeutics
CardiolRxâ„¢ is currently being evaluated in the ARCHER trial, a Phase II multi-national study to evaluate its safety and tolerability as well as its impact on myocardial recovery, in patients …See details»
Cardiol Therapeutics Completes Patient Enrollment in its Phase II ...
Feb 21, 2024 The Company's lead small molecule drug candidate, CardiolRxâ„¢ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the …See details»
Cardiol Therapeutics Announces Positive Topline Data from its …
Administration of CardiolRxâ„¢ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRxâ„¢ also shown to reduce inflammation in patients with elevated …See details»
Press Releases - cardiolrx.com
Dec 15, 2020 Trial designed to investigate the cardioprotective properties of CardiolRxâ„¢ in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, …See details»
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage …
Oct 22, 2024 MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with …See details»
Cardiol Therapeutics Announces Positive Topline Data from its …
Jun 13, 2024 CardiolRxâ„¢ was shown to be safe and generally well-tolerated. MAvERIC-Pilot Study Design. The ongoing MAvERIC-Pilot study is evaluating CardiolRxâ„¢ in 27 adult …See details»
Cardiol Therapeutics Announces $11.25 Million Bought Deal
May 13, 2020 The Company's lead product, CardiolRxâ„¢, is formulated to be the most consistent cannabidiol formulation on the market. CardiolRx is pharmaceutically produced, manufactured …See details»
Cardiol Therapeutics Receives FDA Clearance of Investigational …
Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis Newsfile Corp. Tue, Aug 24, …See details»
Cardiol Therapeutics Announces Pre-Clinical Study Results …
Oct 3, 2022 Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022 Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol …See details»
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 …
Aug 26, 2020 CardiolRx is an extra strength formulation of pharmaceutical cannabidiol that has been formulated to set the highest industry standard for purity, consistency, and stability. …See details»